Rein Therapeutics RNTX
NASDAQ RNTX
$0.80 -0.05 (-5.88%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rein Therapeutics (RNTX) Gains from Sales and Divestitures (2020 - 2023)

Updated

Rein Therapeutics (RNTX) posted Gains from Sales and Divestitures of $10,000 for Q4 2023.

Analysis

Rein Therapeutics (RNTX) Gains from Sales and Divestitures (2020 - 2023) Analysis & Trends

For FY2023, Rein Therapeutics' Gains from Sales and Divestitures came in at -$6,000.

  • In prior years, Rein Therapeutics' Gains from Sales and Divestitures was $66,000 in FY2021 (-23.3%), $86,000 in FY2020 and -$5,000 in FY2019.
  • The Q4 2023 figure stands as the highest quarterly Gains from Sales and Divestitures since Q4 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Rein Therapeutics 53.67 Mn 53.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 10,000.00
Mar 31, 2023 -16,000.00
Dec 31, 2020 20,000.00
Mar 31, 2020 66,000.00
API Access

Rein Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RNTX&period=max&api_key=YOUR_API_KEY